Safety & Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive

See also
Status	Clinical Trial	Phase
Recruiting	`NCT00872495` - Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer
Withdrawn	`NCT05335707` - Longitudinal Geriatric Assessment to Optimize Outcomes of Older Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy
Completed	`NCT03998579` - Physical Rehabilitation Among Patients Undergoing Radical Cystectomy Due to Urinary Bladder Cancer	N/A
Not yet recruiting	`NCT04525781` - Clinicoepidimiological Study and Clinical Outcome in Patients With Urinary Bladder Cancer
Completed	`NCT02897765` - A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer	Phase 1
Recruiting	`NCT05822934` - Carboplatin-gemcitabine Versus Cisplatin- Gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urinary Bladder Cancer	Phase 3
Completed	`NCT06156787` - Patterns of Urinary Bladder Cancer in Darfur, Suda
Completed	`NCT02722538` - Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer	Phase 1
Completed	`NCT02437539` - Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography	Phase 1
Completed	`NCT02139371` - Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography	Phase 0
Completed	`NCT03433924` - An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation in the Chinese MIUBC Patients.
Active, not recruiting	`NCT03132922` - MAGE-A4ᶜ¹º³²T for Multi-Tumor	Phase 1
Completed	`NCT05946369` - Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer
Recruiting	`NCT06307704` - Lung US for PEEP Optimization in Robotic Radical Prostatectomy or Cystectomy Patients	N/A
Completed	`NCT00462488` - Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ	Phase 2
Recruiting	`NCT05621837` - Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
Recruiting	`NCT05644041` - Intravesical Gemcitabine in Patients With NMIBC	Phase 2
Completed	`NCT04635566` - Pharmacological Enhancement for Nocturnal Incontinence in Orthotopic Bladder Substitute	N/A
Recruiting	`NCT04861584` - Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects	Phase 2
Completed	`NCT01836978` - Prehabilitation to Enhance Postoperative Functional Capacity Following Radical Cystectomy	N/A

NCT number	NCT02720367
Study type	Interventional
Source	Taris Biomedical LLC
Contact
Status	Completed
Phase	Phase 1
Start date	January 2016
Completion date	March 2020

Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms